검색결과 : 11건
| No. | Article |
|---|---|
| 1 |
Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities Vohidov F, Andersen JN, Economides KD, Shipitsin MV, Burenkova O, Ackley JC, Vangamudi B, Nguyen HVT, Gallagher NM, Shieh P, Golder MR, Liu J, Dahlberg WK, Ehrlich DJC, Kim J, Kristufek SL, Huh SJ, Neenan AM, Baddour J, Paramasivan S, de Stanchina E, Kc G, Turnquist DJ, Saucier-Sawyer JK, Kopesky PW, Brady SW, Jessel MJ, Reiter LA, Chickering DE, Johnson JA, Blume-Jensen P Journal of the American Chemical Society, 143(12), 4714, 2021 |
| 2 |
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition Xue JY, Zhao YL, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li CC, de Stanchina E, Mazutis L, Risso D, Lito P Nature, 577(7790), 421, 2020 |
| 3 |
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Fencht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW Science, 362(6421), 1416, 2018 |
| 4 |
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao HY, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N Nature, 548(7666), 234, 2017 |
| 5 |
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer Mu P, Zhang ZD, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL Science, 355(6320), 84, 2017 |
| 6 |
Deriving human ENS lineages for cell therapy and drug discovery in Hirschsprung disease Fattahi F, Steinbeck JA, Kriks S, Tchieu J, Zimmer B, Kishinevsky S, Zeltner N, Mica Y, El-Nachef W, Zhao HY, de Stanchina E, Gershon MD, Grikscheit TC, Chen SB, Studer L Nature, 531(7592), 105, 2016 |
| 7 |
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM Nature, 534(7606), 272, 2016 |
| 8 |
A combinatorial strategy for treating KRAS-mutant lung cancer Manchado E, Weissmueller S, Morris JP, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW Nature, 534(7609), 647, 2016 |
| 9 |
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system (vol 516, pg 423, 2014) Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, Lowe SW, Ventura A Nature, 524(7566), 502, 2015 |
| 10 |
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao CY, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA, Pelletier J, Ratsch G, Wendel HG Nature, 513(7516), 65, 2014 |